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The recent development of hybridoma technology has enlarged our under- 
standing of cell surface molecules, especially those of lymphoid organs. T  cell 
leukemia, which is a common neoplasm of the mouse, and its normal counterpart, 
the thymocyte, have been a major focus for studying cell surface antigens (1). It 
has been generally accepted that, in the mouse embryo, thymic stem cells  are 
derived from either the yolk sac  or the fetal liver.  Shortly after the stem cells 
enter into the thymus, they begin to proliferate and give rise to thymocytes in 
the cortex and medulla, where they can be divided into functional subclasses of 
T  iymphocytes having a  wide repertory of antigen specificity (2).  Serological 
analysis has revealed that this process of differentiation of thymic lymphocytes 
involves a number of marked changes in surface antigens, Thy-1, Lyt-l,2,3, TL 
and other  T  cell  differentiation antigens (3-5).  Almost all  of these antigens, 
except for the TL systems, are quantitative rather than qualitative features. The 
presence of TL antigen is restricted to adult thymocytes  and leukemias of thymic 
origin, and the mechanism of regulation of gene coding for this antigen is of 
particular  interest.  However,  no  report  has  yet appeared  that  describes  the 
antigens expressed predominantly on fetal thymocytes and leukemia cells. 
We  previously  reported  that  the  receptor  for  Dolichos  biflorus  agglutinin 
(DBA), 1 which is specific for terminal nonreducing a-linked N-acetyl D-galactos- 
amine (D-GalNAc) residues (6), is selectively expressed on mouse fetal thymocytes 
and some leukemia cells (7,  8). The immunofluorescence study indicated that a 
majority of the  cells  from  the  mouse  embryo thymus (13  d  gestation) were 
brightly stained with fluorescein isothiocyanate (FITC)-conjugated DBA lectin, 
and the proportion of such cells sharply decreased with the increase in gestation 
time.  Unlike other already defined T  cell  antigens, the  DBA receptor  is  not 
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expressed  on  cells  of adult  lymphoid  tissues  including  thymus,  spleen,  lymph 
nodes,  and  bone  marrow.  In  this  report,  production  of a  mouse  monoclonal 
antibody detecting this receptor on fetal thymocytes is  described.  Biochemical 
properties of the  antigen  recognized,  which was  provisionally designated  fetal 
thymocyte antigen-l, FT-1, were also investigated. 
Materials and Methods 
Animals and Leukemias.  A/J, AKR/J, BALB/c, CBA/J, C57BL/6, C3H/HeN, DBA/2, 
NZB, and SJL mice were supplied by the Omura Institute for Laboratory Animals (Zama, 
Kanagawa, Japan).  GR mice were kindly provided by Dr.  T.  Sakakura,  Laboratory of 
Experimental Pathology, Aichi Cancer Center Research Institute, Nagoya, Japan. 
The leukemias used  were kindly given to  us  by Dr.  L. J.  Old  of Memorial Sloan- 
Kettering Cancer  Institute,  New  York,  and  Dr. J.  Hilgers,  The  Netherlands  Cancer 
Institute,  The  Netherlands.  YAC-1  and  GRSL cultured cell lines were maintained  in 
RPMI  1640 medium supplemented with 5% fetal calf serum (FCS). All other leukemias 
were carried in the ascites form. 
Cell Fusion and Cloning.  BALB/c mice were hyperimmunized with 1 ×  107 GRSL cells. 
3 d after the booster injection, 5 ×  107 spleen cells from the mice were fused with X63- 
Ag8.653 cells in the presence of polyethylene glycol (PEG; mol wt 1,500) (9,  I0). Then 
the cells were plated in a  96-well  culture plate (Costar #3596; Costar, Data Packaging, 
Cambridge,  MA)  and  grown  in  medium  containing  hypoxanthine, aminopterin,  and 
thymidine (HAT). 3 wk after the fusion, the culture supernatants were screened in the 
immunofluorescence study.  Cells  from these wells  were cloned by limiting dilution on 
feeder layers of BALB/c thymocytes. A clone derived from one well (M6) was used for 
the study described here. As M6 antibody was determined to be of the IgM isotype, the 
antibody in the supernatant was precipitated by (NH4)2SO4,  and fractionated by Sephadex 
G-200 (Pharmacia Fine Chemicals, Uppsala, Sweden), and used for the experiments. 
Metabolic Labeling and Immunoprecipitation.  Cells of GRSL, a spontaneous leukemia of 
6  $  GR mice, were suspended at 2 ×  10  cells/ml in RPMI 1640 with 5% FCS. [1- H] galactose 
(10.4 Ci/mmol, Amersham, International, Amersham, U.K.) was added at 50 #Ci/ml and 
cells  were incubated at  37°C  in 5%  COs for  16 h.  The biosynthetic labeling was also 
carried out by adding 50 #Ci of [35S] methionine (1,450 Ci/mmol, Amersham) to 2 ×  106 
cells in Minimum Essential Medium (MEM) (methionine free) with 2% FCS for 16 h. Cells 
were washed twice and extracted in 1 ml of lysis buffer (0.5% Nonidet P-40 [NP-40], 10 
mM Tris HCI pH 7.5, 150 mM NaCI,  1 mM MgCI~, 0.1% NAN3, 1 mM phenylmethylsul- 
fonyl fluoride), with gentle vortex mixing for 30 min on ice. 
For immunoprecipitation, the lysate was incubated with 20 #1 of anti-FT-1 for 2 h at 
0°C, and then with 50 #1 of goat anti-mouse IgM serum for an additional 10-20 h. The 
resulting  immune  complex was  mixed with  200  ~1 of 10%  fixed Staphylococcus aureus 
Cowan I strain organisms (Bethesda Research Laboratories, Inc., Gaithersburg, MD) for 
60 min at 0°C. The precipitate was washed extensively and then bound antigens were 
released by boiling for  3  min  in  sample  buffer containing 20%  glycerol, 4%  sodium 
dodecyl sulfate (SDS),  120 mM Tris HCI, pH 6.8, and 0.005% bromphenol blue with or 
without 5% 2-mercaptoethanol. 
Immunofluorescence and Qvtotoxicity Test.  For tissue distribution studies, 1.0 x  106 lymph- 
oid cells were incubated for 30 min at 4°C in 50 IA of MEM  containing 5 t~g of biotin- 
conjugated anti-FT-1. The cells were then washed three times and stained for 30 min at 
4°C with 1/~g of FITC-avidin in 50 #1 of MEM. FITC-monoclonal anti-Thy-l.2 antibody 
used at a  1:40 dilution was kindly provided by Dr. K. Okumura,  University of Tokyo, 
Tokyo, Japan.  1 #g of FITC-DBA in 50/~! of MEM was used for staining. The absorption 
test and  complement-dependent cytotoxicity assay  were  carried  out according to  the 
method described previously (11). 
Isolation of DBA Receptors.  DBA receptors were isolated from GRSL cells according to 
the  method described previously (8).  Briefly, the  detergent  lysate of GRSL cells  was 
applied to a DBA-Sepharose 4B column equilibrated with the elution buffer (0.5% NP- KASAI  ET  AL. 
TABLE  I 
Tissue Distribution of FT-1 Antigen 
Fluorescent  Absorption 
Tissue (A/J)  staining (%)  with 
Fetal mouse (15th gestation day) 
Thymus  58  NT* 
Liver  0  NT 
Adult mouse (8 wk) 
Thymus  0  --* 
Spleen  0  -- 
Lymph node  0  -- 
Bone marrow  0  -- 
Liver  NT  -- 
Kidney  NT  -- 
Brain  NT  -- 
Control GRSL  100  +0 
Various tissues were examined for FT-1 antigen by immunofluorescent 
staining as described in Materials and Methods. The presence of  antigen 
on adult lymphoid tissues  and homogenized liver, kidney, and brain 
tissues was also determined by an absorption test. 2 vol of diluted M6 
antibody, one twofold dilution below its endpoint, and 1 vol of packed, 
washed cells were mixed and incubated for 30 min at 4°C. After removal 
of the absorbing cells by centrifugation, the residual cytotoxic activity 
against GRSL cells was tested. 
NT: not tested. 
-: not absorbed. 
+: absorbed. 
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40, 10 mM Tris-HC1 buffer, pH 7.5 with 150 mM NaCI and 1 mM CaCI2). DBA-Sepharose 
4B was prepared by coupling DBA (E. Y. Laboratories, San Mateo, CA) to CNBr (cyanogen 
bromide)-activated Sepharose 4B (Pharmacia). After the column was washed, the receptors 
were eluted from the affinity column by 0.1  M N-acetyl-galactosamine. 
Polyacrylamide Gel Electrophoresis (PAGE) and Fluorography.  The  DBA receptors were 
fractionated by 7.5%  SDS-PAGE under reducing or nonreducing conditions. After the 
electrophoresis, the gels were stained with Coomassie Brilliant blue, destained with  10% 
acetic acid and then processed for fluorography. Briefly, the gels were soaked in  10 vol 
of 1 M  sodium salicylate for 30 min (12) and dried on Whatman 3  MM paper and then 
exposed to X-ray film (Kodak X-Omat AR) at -70°C. 
Two-dimensional Gel Electrophoresis.  FT-1  antigens  labeled with  [3HI  galactose were 
electrophoresed in two dimensions according to the method developed by O'Farrell (13). 
The first dimension separation was by nonequilibrium pH-gradient electrophoresis. The 
second dimension SDS gel electrophoresis was carried out in 10-16% acrylamide gradient 
gel. 
Results 
Tissue Distribution.  Cell hybridization was performed between BALB/c mye- 
Ioma,  X63-Ag8.653  cells,  and  the  lymphocytes of BALB/c  mice  that  were 
immunized with GRSL cells. One of the hybrids, M6, which reacted with fetal 
thymocytes but  not  with  adult  thymocytes, was  subcloned  twice  by  limiting 
dilution. 
Cells from different tissues of A/J mice were incubated with the biotinylated 
M6 antibody and then stained with FITC-avidin. As summarized in Table I, M6 974  FT-I,  A  NEW  LEUKEMIA  ANTIGEN 
TABLE  II 
Change of FT-1 ÷ and Thy-1 ÷ Cells in the Thymus at Different 
Embryonic Stages of the A/J Mouse 
Gestation day 
% Immunofluorescence-positive cells 
FT-1  Thy-1 
13  92  0 
14  76  22 
16  41  60 
18  7  91 
Fetal thymocytes positive for FT-1  or Thy-1 were determined by immu- 
nofluorescent staining as described in Materials and Methods. 
antibody brightly stained fetal thymocytes, whereas there were no positive cells 
in fetal liver and adult thymus. No positive cells were observed in the spleen, 
lymph node, or bone marrow. The absorption study, testing for residual cyto- 
toxicity of M6 antibody against GRSL  cells, confirmed the above results and 
showed  that  the  antibody  did  not  react  with  the  nonlymphoid tissues  liver, 
kidney, and brain.  Therefore, the antigen detected by M6 antibody was provi- 
sionally called fetal thymus antigen-l, FT-1. 
Ontogeny  of FT-1  Antigen.  Strain  distribution  studies showed that anti-FT-1 
(M6 antibody) reacted with the fetal thymocytes of all the inbred mouse strains 
examined, including BALB/c.  As  shown  in  Table  II,  the proportion  of fetal 
thymocytes positive for FT-1  sharply decreased with increase in gestation time. 
A small percentage of positive cells still remained in the thymus of neonatal mice, 
but almost completely disappeared from that of adult mice (7-8 wk). In contrast, 
Thy-l-positive cells increased in  inverse proportion  in  the fetal thymus. The 
ontogenic appearance of FT-! antigen seemed to be almost completely identical 
to that of DBA lectin receptor as reported previously (7). 
FT-1  Antigen  on Leukemia  Cells.  Since anti-FT-1  antibody was raised against 
GRSL cells, it can be assumed that FT-1  antigen is also expressed on the other 
leukemia cells.  Therefore, a  number of mouse leukemias were tested for the 
expression of FT-1  antigen (Table III) by an immunofluorescence study using 
biotinylated anti-FT-1 and FITC-avidin. In addition to GRSL cells, cells of 6 out 
of 14  leukemias tested were brightly stained; ASL-1,  RADA-1, and YAC-1  in 
strain A/J, RL~-I in strain BALB/c, and DBA,SL-2 in strain DBA were positive, 
but AKSL-2,  BW5147,  and  K36  derived from a  high leukemic mouse strain, 
AKR, were all negative. 
Biochemical  Characterization  of FT-1 Antigen.  For the estimation of the molec- 
ular weight of FT-1 antigen, immunoprecipitation experiments were carried out 
with NP-40-solubilized antigen from [3H] galactose-labeled GRSL cells, and then 
the precipitates were run on 7.5% acrylamide SDS gels. The fluorograph shown 
in Fig.  1 indicates that the apparent molecular weight of FT-1  is ~130,000.  A 
similar result was obtained when immunoprecipitates were derived from cells 
metabolically labeled by the incorporation of [~S]methionine, although 55,000 
and other minor bands were also obtained (Fig. 2). These results clearly indicate 
that FT-1  antigenic determinants of the leukemic cells reside on the  130,000- 
dalton glycoproteins. Further biochemical characterization of FT-1  antigen by KASAI  ET  AL. 
TABLE  III 
Expression  of FT-1 Antigen and DBA Receptor on Various Leukemia 
Cells 
Tumor  Host strain  FT-1  DBA receptor 
ASL-1  A/J  +  + 
RADA-1  A/J  +  + 
YAC-1  A/J  +  + 
AKSL-2  AKR  -  - 
BW5147  AKR  -  - 
K36  AKR  -  - 
BALB, RV-I  BALB/c  -  - 
MOPC-70A  BALB/c  -  - 
RLd-1  BALB/c  +  + 
EL-4  C57BL/6  -  - 
ERLD  C57BL/6  -  - 
DBA, SL-2  DBA  +  + 
P815  DBA  -  - 
GRSL  GR  +  + 
Expression of FT-1 antigens and DBA receptors on various leukemia cells 
was determined by immunofluorescent staining. 
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FIGURE  1.  SDS-PAGE analysis of the FT-I antigen immunoprecipitated from [SH] galactose- 
labeled GRSL cells. GRSL cells were cultured with [SH] galactose for  16 h  and treated with 
0.5%  NP-40.  The  lysates  were  immunoprecipitated  with  anti-FT-1  followed  by  goat  anti- 
mouse IgM, and collected with fixed S. aureus. The immunoprecipitates were run on 7.5% 
polyacrylamide gels under reducing (.4) and nonreducing conditions (B). K, ×  10  s. 
two-dimensional  gel  electrophoresis  confirmed  the  above  results  indicating  size 
homogeneity.  As  shown  in  Fig.  3,  however,  the  fluorographic  pattern  of  [3H] 
galactose-labeled  FT-1  antigen  shows  a  family  of  glycoproteins  with  extensive 
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FIGURE  2.  SDS-PAGE analysis of the FT-1 antigen immunoprecipitated from [ssS] methio- 
nine-labeled GRSL cells. GRSL cells were cultured with [ssS] methionine for 16 h and treated 
with 0.5%  NP-40. The lysates were immunoprecipitated with anti-FT-1 (A) or normal mouse 
serum (B), followed by anti-mouse Ig and goat anti-rabbit Ig. The immunoprecipitates were 
run on 7.5% polyacrylamide  gels under reducing conditions. 
FIGURE  3.  Two-dimensional gel electrophoresis of FT-1 antigen immunoprecipitated from 
[3HI galactose-labeled  GRSL cells. The first dimension separation was by nonequilibrium pH- 
gradient electrophoresis (basic protein on the right). The second dimension separation (top to 
bottom) was by SDS-PAGE on 10-16% acrylamide gradient gels. 
Relationship between FT-I Antigen and DBA Receptor.  Concerning  the ontogeny 
and  the expression of leukemia cells of FT-1  antigen  (Tables II and  III), there 
are a  number  of similarities between  FT-1  antigen and DBA lectin receptors.  In 
order to clarify the relationship between these two molecules on GRSL  leukemic KASAI  ET  AL.  977 
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FIGURE 4.  Residual cytotoxicity of anti-FT-1 after absorption with DBA receptors. 50 t~l of 
anti-FT-1 was absorbed with DBA receptors (5 t~g), and then tested for residual cytotoxicity 
against FT-1 ÷ YAC-1 cells. 
FIGURE 5.  Absorption of [3H] galactose-labeled DBA receptor by anti-FT-1  demonstrated 
by immunoprecipitation. DBA receptors from [SH] galactose labeled GRSL cells were purified 
by  DBA-Sepharose 4  B  column  and  were subjected  to  SDS-PAGE analysis  (A). The  DBA 
receptors were immunoprecipitated either with anti-FT-I or a control, unrelated IgM hybri- 
doma antibody, anti-FT-2 (Takashi et al., manuscript in preparation),  followed by goat anti- 
mouse  IgM,  and  collected with  fixed S.  aureus.  After the  precipitate  was  spun  down,  the 
supernatant  was  subjected to  SDS-PAGE analysis,  lmmunoprecipitation  with anti-FT-1  re- 
moved the band (B), whereas that with anti-FT-2 did not (C). 
cells, the following experiments were carried out. First, GRSL tumor cells were 
lysed in  0.5%  NP-40 extraction  medium and  the supernatant  was applied to a 
column of DBA Sepharose 4B. 5 #g of the receptor molecules eluted from the 
DBA Sepharose 4B column by 0.1  M N-acetylgalactosamine was mixed with 50 
~1 of anti-FT-1  antibody. After the precipitate was spun down, the supernatant 
was serially diluted and tested for residual cytotoxicity against YAC-1 cells. Fig. 
4 shows that the cytotoxic activity of anti-FT-1  antibody was absorbed with DBA 
receptor. Second, it was demonstrated that DBA receptors were immunoprecip- 978  FT-I,  A  NEW  LEUKEMIA  ANTIGEN 
itated  by anti-FT-1.  Although  the  molecular  weight  of [3H]galactose-labeled 
DBA receptors  was slightly  lower than  that  of FT-1  (Fig.  5A),  these receptor 
molecules were specifically absorbed with anti-FT-1  and no precipitation  band 
was  observed  as  shown  in  Fig.  5B.  However,  an  unrelated  IgM  hybridoma 
antibody, anti-FT-2  used as a  control, could not absorb DBA receptors so that 
the precipitation  band remained  (Fig.  5C).  These results strongly suggest that 
the FT-1 molecule resides on the DBA lectin receptor. 
Discussion 
The present study demonstrated a unique cell surface antigen designated FT- 
1, which is expressed on fetal thymocytes of all mouse strains examined, but not 
on thymocytes or other lymphoid cells of adult mice. This antigen is present also 
on some leukemia cells, and it is found on the receptor molecules for DBA lectin 
on GRSL leukemia cells. One of the interesting features of FT-1 antigen is the 
timing of its expression in connection with thymocyte ontogeny. A  majority of 
fetal thymocytes at 13 d gestation express FT-1 antigen, whereas no positive cells 
are found in the fetal liver. Therefore, FT-1 antigen seems to appear as soon as 
the  stem  cells have  reached  the  thymus.  The  proportion  of FT-1 ÷ cells then 
declined  sharply  with  increase  in  the  time  of gestation,  while  Thy-1 +  cells 
increased in inverse proportion. The results suggest that FT-1- stem cells acquire 
FT-1 antigen, and then differentiate into Thy-1 + FT-1- cells under the influence 
of thymic epithelial  cells, although  the possibility remains that Thy-1 + cells are 
derived from a  minor  FT-1- population in the embryonic thymus. In neonatal 
mice, a small percentage of FT-1 ÷ cell still remain in the thymus, but these cells 
almost completely disappear from the adult thymus, spleen,  lymph nodes, and 
bone marrow. The differentiation of mouse T  cells has been extensively studied 
by use of cell surface antigens  (14-16).  In the first stage of intrathymic  differ- 
entiation,  stem  cells migrate  into  the cortical  area  of the  thymus,  where  they 
acquire  Thy-1,  TL,  and  Lyt antigens.  These  cortical  cells,  which  have  Thy-1 
antigen in high density, are cortisone-sensitive and relatively large in size.  With 
further maturation,  TL antigens are lost and then Thy-1  diminishes in density. 
Thereafter,  they migrate  to the thymus medulla where they are medium-sized 
cells and are resistant to cortisone. Finally they migrate from the thymus medulla 
to the peripheral  lymphoid organs.  In contrast  to the differentiation  sequence 
within  the  adult  thymus as described above,  little  is known about  the  surface 
antigens  of fetal thymocytes before they acquire a  number  of T  cell antigens. 
Although  rabbit anti-asialo  GM1  antibody with potent anti-natural  killer (NK) 
activity (17) has been shown to react with fetal thymocytes (18), it is evident that 
anti-FT-1  marks fetal thymocytes more specifically. Thus, FT-1 antigen will be 
a  useful marker  for studying the early stages of T  cell ontogeny. Experiments 
are now in progress to elucidate the mechanism of the acquisition as well as the 
processing of FT-1  in the thymus of the fetal mouse. 
It is frequently said that  the presence of embryonic tissue antigen  is shared 
with tumor antigen.  However, in lymphoid tissues, such antigens have not ever 
been serologically defined to date. Since FT-1 is present on fetal thymocytes and 
some leukemia cells, this is probably the first example of an oncofetal antigen of 
a  mouse T  cell leukemia.  Therefore,  FT-1  antigen  will  be as important  as TL KASAI ET  AL.  979 
antigen for understanding the mechanism underlying the activation of normally 
silent genetic information  in leukemic cells. 
The molecular weight of FT-1 antigen on leukemic cells was estimated to be 
130,000  by means of [SH]galactose labeling followed by immunoprecipitation. 
FT-1  antigen  biosynthetically labeled with  [35S] methionine also appeared as a 
major band with a mol wt 130,000. The other minor bands, especially the 55,000 
band,  were also brought down.  It is possible to assume that  55,000 molecule is 
an  intracellular  form  of FT-1  antigen  that  is  not  detected by sugar  labeling. 
However, further  experiments are necessary to study kinetics of FT-1  antigen 
synthesis in  the  cells.  Two-dimensional  gel electrophoresis revealed  that  FT-1 
antigenic determinants appear to reside on a family of glycoproteins with exten- 
sive charge heterogeneity.  In these biochemical studies,  we did not succeed in 
detecting FT-1 molecules on fetal thymocytes so far attempted, probably because 
the number of fetal thymocytes used for these experiments was not sufficient. 
The  molecule  defined  by  anti-FT-1  is  clearly  different  from  other  T  cell 
differentiation antigens in terms of biochemical properties and tissue distribution. 
Considering the reciprocal appearance of Thy-1 ÷ cells and FT-1 ÷ cells, it could 
be possible to  assume  that  the  FT-1  molecule  is  a  precursor  of other  T  cell 
differentiation antigens.  Further biochemical and genetic analysis of FT-1  anti- 
gen will contribute to understanding of the ontogenic development of T  cells as 
well as leukemogenesis of T  cell leukemias. 
Summary 
A  mouse monoclonal  antibody (IgM)  was obtained by cell  hybridization  be- 
tween  X63-Ag8.653  myeloma cells and  spleen cells from a  BALB mouse that 
was  immunized  with  GRSL  leukemia  cells  of the  GR  strain.  This  antibody 
identified a  unique  fetal antigen,  which  is expressed exclusively on embryonic 
thymocytes of all strains tested. Therefore, the antigen defined was named fetal 
thymus antigen-l,  FT-1. The proportion of FT-1 ÷ fetal thymocytes detected by 
immunofluorescence  assay  sharply  decreases  as  gestation  time  increases,  and 
finally they disappear from the thymus. On the other hand, Thy-1 + cells increase 
in  inverse  proportion.  The  immunofluorescence  studies  and  absorption  tests 
showed that FT-1 antigen is not detectable on brain,  liver, kidney, or lymphoid 
tissue cells of adult  mice.  However, it  is  expressed on  some leukemia  cells of 
various mouse strains,  which  demonstrated  that  this  is the first example of an 
oncofetal antigen  of a  mouse leukemia.  The molecular weight of FT-1  antigen 
on leukemia cells was estimated to be 130,000 by means of biosynthetic labeling 
with [SH]galactose and [SSS]methionine. The two-dimensional gel electrophoresis 
pattern  of FT-1  antigen  shows a  family of glycoproteins with extensive charge 
heterogeneity.  It  was also  shown  that  the  FT-1  antigen  molecule  carries  the 
receptor for DBA lectin. 
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